EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Remdesivir and Obeldesivir Retain Potent Antiviral Activity Against SARS-CoV-2 Omicron Variants

Lauren Rodriguez, J Lizbeth Reyes Zamora, Dong Han, Jasmine Moshiri, Nadine Peinovich, Clarissa Martinez, Pui Yan Ho, Jiani Li, Thomas Aeschbacher, Ross Martin, Andrew Pekosz iD, John P Bilello iD und 2 weitere

Viruses · 2025

DOI: 10.3390/v17020168 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von Lauren Rodriguez und 13 weiteren Autor:innen. Beteiligte Einrichtung: Gilead Sciences, Inc., Foster City, CA 94404, USA. Hauptthemen laut MEDLINE: SARS-CoV-2, Antiviral Agents, Adenosine Monophosphate, Alanine. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As new SARS-CoV-2 variants continue to emerge, it is important to evaluate the potency of antiviral drugs to support their continued use. Remdesivir (RDV; VEKLURY®) an approved antiviral treatment for COVID-19, and obeldesivir (ODV) are inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase Nsp12. Here we show these two compounds retain antiviral activity against the Omicron variants BA.2.86, BF.7, BQ.1, CH.1.1, EG.1.2, EG.5.1, EG.5.1.4, FL.22, HK.3, HV.1, JN.1, JN.1.7, JN.1.18, KP.2, KP.3, LB.1, XBB.1.5, XBB.1.5.72, XBB.1.16, XBB.2.3.2, XBC.1.6, and XBF when compared with reference strains. Genomic analysis identified 29 Nsp12 polymorphisms in these and previous Omicron variants. Phenotypic analysis of these polymorphisms confirmed no impact on the antiviral activity of RDV or ODV and suggests Omicron variants containing these Nsp12 polymorphisms remain susceptible to both compounds. These data support the continued use of RDV in the context of circulating SARS-CoV-2 variants and the development of ODV as an antiviral therapeutic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2Antiviral AgentsAdenosine MonophosphateAlaninePyrazinesHumansCOVID-19 Drug TreatmentCOVID-19Chlorocebus aethiopsVero CellsViral Nonstructural ProteinsCoronavirus RNA-Dependent RNA PolymeraseAdenosine

Stichwörter der Autor:innen

COVID-19Nsp12Omicron variantsSARS-CoV-2genotypingphenotypingremdesivir

Substanzen

remdesivirAntiviral AgentsAdenosine MonophosphateAlanineGS-441524PyrazinesNSP12 protein, SARS-CoV-2Viral Nonstructural ProteinsCoronavirus RNA-Dependent RNA PolymeraseAdenosine

Autor:innen und Institutionen

  • Gilead Sciences, Inc., Foster City, CA 94404, USA.
  • Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.

ORCID-Profile: Andrew Pekosz, John P Bilello

Förderung

  • Gilead Sciences, Inc.

Zitieren

APA

Rodriguez, L., Zamora, J. L. R., Han, D., Moshiri, J., Peinovich, N., Martinez, C., Ho, P. Y., Li, J., Aeschbacher, T., Martin, R., Pekosz, A., Bilello, J. P., Perry, J. K., & Hedskog, C. (2025). Remdesivir and Obeldesivir Retain Potent Antiviral Activity Against SARS-CoV-2 Omicron Variants. Viruses. https://doi.org/10.3390/v17020168

Vancouver

Rodriguez L, Zamora JLR, Han D, Moshiri J, Peinovich N, Martinez C, et al. Remdesivir and Obeldesivir Retain Potent Antiviral Activity Against SARS-CoV-2 Omicron Variants. Viruses. 2025. doi:10.3390/v17020168

BibTeX
@article{Rodriguez2025,
  author = {Rodriguez, Lauren and Zamora, J Lizbeth Reyes and Han, Dong and Moshiri, Jasmine and Peinovich, Nadine and Martinez, Clarissa and Ho, Pui Yan and Li, Jiani and Aeschbacher, Thomas and Martin, Ross and Pekosz, Andrew and Bilello, John P and Perry, Jason K and Hedskog, Charlotte},
  title = {Remdesivir and Obeldesivir Retain Potent Antiviral Activity Against SARS-CoV-2 Omicron Variants},
  journal = {Viruses},
  year = {2025},
  doi = {10.3390/v17020168}
}
Kostenlos starten →